Cardiology

A recent study found no benefits of immediate angiography over a delayed or selective strategy with respect to the 30-day risk of death from any cause.

ENVISAGE-TAVI AF is the first trial to compare edoxaban against standard of care in patients who have atrial fibrillation and have undergone successful TAVR.

Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).

Net adverse clinical events occurred in 165 patients in the abbreviated-therapy group and 172 in the standard therapy group in patients at high bleeding risk after PCI.

The direct-acting oral anticoagulant benefitted prevention of adverse clinical events, but was associated with worse major bleeding.

A randomized trial presented at ESC Congress 2021, results of SMART-MI demonstrate use of ICMs could help improve detection of arrhythmia and improve outcomes in a patient population that would normally not be eligible for ICM implantation.

New EMPEROR-Preserved findings show the SGLT-2 inhibitor significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status.

A pilot study found use of drones to deliver AEDs to patients with out-of-hospital cardiac arrest could improve response times compared to traditional emergency services.

An analysis of adherence to guideline-directed management at 1-year after ACS provides data suggesting optimal adherence could prolong event-free life expectancy by a median of 7.5 years.

A study presented at ESC 2021 details a significant rise in rates of cardiac arrests with a secondary diagnosis of opioid use in the United States from 2012-2018.

Risk for major bleeding was found to be higher in patients treated with aspirin, ticagrelor compared to aspirin alone.

Globally, 331 million women and 317 million men had hypertension in 1990, compared with 626 million women and 652 million men in 2019.

The updated transcatheter aortic valve replacement system incorporates a supra-annular valve design, with a redesigned catheter tip and 4 valve sizes.

Announced on August 24, rivaroxaban (Xarelto) has received its ninth indication from the US FDA. This time, the FDA has approved a label expansion to include patients with symptomatic peripheral artery disease who have undergone lower extremity revascularization.

With approval of the Evolut FX TAVR System announced on August 24, the Evolut TAVR Platform is now indicated for symptomatic severe aortic stenosis across all patient risk categories.

The newest indication for the anticoagulant is based on phase 3 VOYAGER PAD findings showing benefit in reduced risk of major cardiovascular events among post-revascularization patients with PAD.

Dr. Gregory Weiss tackles the topic of physician burnout in cardiology and offers perspective on the most common causes as well as possible methods of intervention to mitigate the impact of burnout.

New data suggests patients with a history of diabetes, hypertension, or cardiovascular disease were at increased risk of worsening hypoxemia compared to their counterparts without these conditions.

A new meta-analysis by investigators from Johns Hopkins details the prevalence of UACR testing in patient populations at increased risk of albuminuria, suggesting less than 40% of patients with diabetes underwent UACR testing and this figure dropped to less than 5% among patients with hypertension.

Pictorial data on carotid intima-media thickness and presence of carotid plaques can improve prescription of lipid-lowering drugs.

Data from a cross-sectional analysis details contemporary trends in industry payments and authorship of commentaries related to recent RCTs examining cardiovascular interventions.

A new study leveraging data from the PINNACLE registry provides an overview of racial, socioeconomic, geographic, and practice-level factors that play a role in odds of receiving a prescription for a PCSK9 inhibitor among patients with ASCVD and suboptimal LDL-C.

All NOACs had a lower risk of stroke or SE compared to warfarin, including apixaban, dabigatran, and rivaroxaban.

Patients with severe mental health issues often are linked to health inequalities that contribute to a shorter life expectancy than the general population.

Data show 15% of authors in this analysis reported financial associations with trial sponsors in invasive cardiovascular intervention studies.